Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Aducanumab (BIIB037)
DRUG
2 trials
Sponsors
Biogen
Conditions
Alzheimer's Disease
Phase 3
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Terminated
NCT02477800
Biogen
Alzheimer's Disease
Start: 2015-08-13
End: 2019-08-08
Updated: 2021-09-02
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Terminated
NCT02484547
Biogen
Alzheimer's Disease
Start: 2015-09-15
End: 2019-08-05
Updated: 2021-09-02
Related Papers
Spectrum of amyloid-related imaging abnormalities associated with aducanumab treatment: a case series report
BMC Neurology
2026-07-30
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease
Alzheimer s & Dementia
2025-06-01
6 citations
Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease.
2025-05-24
2 citations
Anticorpos anti-amilóides para o tratamento da doença de Alzheimer
Jornal de Assistência Farmacêutica e Farmacoeconomia
2024-11-30
1 citations
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies
Neurology
2023-12-28
34 citations
Simulation‐based effect size analysis in the absence of drug effects to inform the design of clinical trials in Alzheimer’s disease
Alzheimer s & Dementia
2023-12-01
1 citations
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
2023-01-01
16 citations
Autopsy Results from the ENGAGE Trial of Aducanumab: Lessons from Co‐pathology
Alzheimer s & Dementia
2022-12-01
Baseline EMBARK Data From EMERGE, ENGAGE, and PRIME Participants in the EMBARK Redosing Study (N3.002)
Neurology
2022-05-03
1 citations
Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease
Clinical Pharmacology & Therapeutics
2022-01-31
14 citations
Commentary on: A call for better reporting of trials using surrogate primary endpoints
Alzheimer s & Dementia Translational Research & Clinical Interventions
2022-01-01
Considerations for the real‐world management of ARIA from the aducanumab phase 3 studies EMERGE and ENGAGE
Alzheimer s & Dementia
2021-12-01
1 citations
Item‐level analysis of clinical measures in patients with early symptomatic Alzheimer’s disease following treatment with high‐dose aducanumab in the phase 3 study EMERGE
Alzheimer s & Dementia
2021-12-01
1 citations
Reductions in biomarkers of Alzheimer’s disease pathophysiology following treatment with aducanumab were associated with slowing in clinical decline
Alzheimer s & Dementia
2021-12-01
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
JAMA Neurology
2021-11-22
539 citations
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
2021-08-23
33 citations
Antibodies to watch in 2020.
2020-01-01
328 citations
Baseline Characteristics From ENGAGE and EMERGE: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease (P4.1-001)
Neurology
2019-04-09
15 citations
Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
PubMed
2017-01-01
86 citations